5 completed, 2 active not recruiting. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Active not recruiting 2 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
Follow Grade 2 Follicular Lymphoma: new trials by email Literature Review of Grade 2 Follicular Lymphoma trials Research Report on Grade 2 Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas Anti-OX40 Antibody BMS 986178, Laboratory Biomarker Analysis, Radiation Therapy - B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Ronald Levy | 14 | 2018-04-09 | 2024-12-11 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Active not recruiting | Beth Christian | 22 | 2017-02-21 | 2026-09-24 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101 - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 21 | 2016-11-07 | 2024-10-16 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia cefepime hydrochloride - Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 70 | 2011-02-01 | 2018-07-18 |
Lymphoma, Follicular (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Mantle-Cell (5) · Lymphoma, B-Cell (4) · Lymphoma, Large B-Cell, Diffuse (4) · Burkitt Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Non-Hodgkin (2) · Anemia (1) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Hodgkin Disease (1) · Leukemia, Hairy Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, Non-Hodgkin (5) · Hematologic Diseases (4) · Chronic Disease (3) · DNA Virus Infections (3) · Disease Attributes (3) · Epstein-Barr Virus Infections (3) · Herpesviridae Infections (3)
Radiation (2) · Radiotherapy (2) · ibrutinib (2) · obinutuzumab (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Cefepime (1) · Lenalidomide (1) · acalabrutinib (1) · axicabtagene ciloleucel (1) · pembrolizumab (1) · venetoclax (1)
Alexey Danilov, MD (1) · Beth Christian (1) · Kami Maddocks (1) · Robert Lowsky (1) · Ronald Levy (1) · University of Washington (1) · Wake Forest University Health Sciences (1)
United States (7)
Ronald Levy (2) · Ajay Gopal (1) · Beth Christian, MD (1) · Craig Okada, M.D. (1) · John Williamson (1) · Kami Maddocks, MD (1) · Michael Khodadoust (1)
PMID 34780125, PMID 34196037, PMID 35135810, PMID 37939259
R35CA197353 (2), P30CA016058 (1)